Raymond James initiated coverage on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $20.00 price objective on the stock.
Other research analysts also recently issued reports about the stock. Piper Sandler reaffirmed an overweight rating and issued a $12.00 target price on shares of Black Diamond Therapeutics in a research report on Wednesday, July 3rd. Wedbush increased their target price on shares of Black Diamond Therapeutics from $10.00 to $16.00 and gave the company an outperform rating in a research report on Monday, April 8th. Finally, HC Wainwright reaffirmed a buy rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research report on Friday, June 7th.
Get Our Latest Research Report on Black Diamond Therapeutics
Black Diamond Therapeutics Trading Down 5.0 %
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.09. On average, analysts predict that Black Diamond Therapeutics will post -1.47 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new position in Black Diamond Therapeutics during the 1st quarter worth $82,000. SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics during the 2nd quarter worth $108,000. Jump Financial LLC grew its position in Black Diamond Therapeutics by 245.0% during the 4th quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock worth $109,000 after purchasing an additional 27,616 shares during the last quarter. Pale Fire Capital SE purchased a new position in Black Diamond Therapeutics during the 4th quarter worth $144,000. Finally, Rhumbline Advisers boosted its holdings in shares of Black Diamond Therapeutics by 10,334.3% in the second quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock valued at $218,000 after acquiring an additional 46,401 shares in the last quarter. 95.47% of the stock is owned by hedge funds and other institutional investors.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- How to Evaluate a Stock Before Buying
- Should You Invest in Bitcoin? Pros and Cons
- What is the Euro STOXX 50 Index?
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- ESG Stocks, What Investors Should Know
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.